04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

CellMax reports colorectal cancer diagnostic data

CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. The single-site, Taiwanese trial enrolled 620 adults who were undergoing a routine colonoscopy...
23:24 , Jan 17, 2018 |  BC Extra  |  Clinical News

Exact Sciences falls on CellMax cancer diagnostic data

Exact Sciences Corp. (NASDAQ:EXAS) was off $5.27 (10%) to $47.68 on Wednesday after CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity....
07:00 , Jul 26, 2016 |  BC Extra  |  Financial News

CellMax raises $9M in series A-1

Diagnostics company CellMax Life Inc. (Sunnyvale, Calif.) said it raised $9 million in a series A-1 financing led by Artiman Ventures. Taiwanese investors, including Acer Inc. (Taiwan:2353; LSE:ACID) founder Stan Shih, also participated. The company...